Nurix Therapeutics Ownership | Who Owns Nurix Therapeutics?


OverviewForecastRevenueFinancialsChart

Nurix Therapeutics Ownership Summary


Nurix Therapeutics is owned by 107.22% institutional investors, 1.08% insiders. Blackrock is the largest institutional shareholder, holding 12.42% of NRIX shares. Vanguard MStar Total Stk Mkt Idx Invest is the top mutual fund, with 3.17% of its assets in Nurix Therapeutics shares.

NRIX Ownership Benchmark


TypeName% Inst% Insiders% Retail
StockNurix Therapeutics107.22%1.08%-8.30%
SectorHealthcare Stocks 244.59%12.11%-156.70%
IndustryBiotech Stocks 379.61%11.70%-291.31%

Institutional Shareholders


Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Blackrock6.82M12.42%$142.33M
Blackrock funding, inc. /de8.77M7.97%$212.77M
Vestal point capital, lp8.05M7.31%$195.29M
Deep track capital, lp7.74M7.03%$187.69M
Rubric capital management lp7.23M6.57%$175.35M
Vanguard group5.95M6.26%$112.86M
Fmr5.49M4.98%$133.07M
Price t rowe associates inc /md/5.44M4.94%$131.89M
Morgan stanley4.76M4.33%$115.54M
State street4.68M4.25%$113.47M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Redmile group4.07M6.64%$98.83M
Vestal point capital, lp8.05M4.56%$195.29M
Deep track capital, lp7.74M2.73%$187.69M
General atlantic3.03M2.53%$73.56M
Foresite capital management v265.00K1.77%$6.43M
Rubric capital management lp7.23M1.61%$175.35M
Kynam capital management, lp1.19M1.60%$28.98M
Perceptive advisors4.32M1.57%$104.81M
Rhenman & partners asset management ab684.25K1.57%$16.60M
Soleus capital management1.47M1.22%$35.54M

Top Buyers

HolderShares% AssetsChange
Rubric capital management lp7.23M1.61%4.75M
Blackrock6.82M0.00%2.24M
Price t rowe associates inc /md/5.44M0.01%2.15M
Vestal point capital, lp8.05M4.56%1.55M
Vanguard group5.95M0.00%1.46M

Top Sellers

HolderShares% AssetsChange
Redmile group4.07M6.64%-3.66M
Commodore capital lp---2.27M
Deutsche bank ag\151.45K0.00%-2.14M
Longaeva partners---1.49M
Ra capital management---1.33M

New Positions

HolderShares% AssetsChangeValue
Sixth street partners management company833.30K0.00%833.30K$20.22M
Sofinnova investments524.10K0.66%524.10K$12.71M
Arrowstreet capital, limited partnership477.14K0.01%477.14K$11.58M
First trust advisors lp360.85K0.01%360.85K$8.75M
Norges bank318.80K0.00%318.80K$6.01M

Sold Out

HolderChange
Twin peaks wealth advisors-1.00
Mai capital management-8.00
Nelson, van denburg & campbell wealth management group-9.00
Federated hermes-15.00
Amundi-17.00

Institutional Ownership Trends


DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Jun 30, 20262169.09%118,021,8810.83%1070.95%1142.70%6448.84%
Mar 31, 20261923.23%115,991,7392.27%1050.62%107-19.55%4250.00%
Dec 31, 202539-77.59%15,163,987-82.11%150.16%26-68.67%7-88.14%
Sep 30, 202546-72.12%9,091,319-89.71%100.10%18-80.43%17-59.52%
Jun 30, 2025164-4.09%88,304,1285.07%1051.04%91-3.19%42-17.65%

Top Mutual Funds Shareholders


HolderShares% HoldingChange
Vanguard MStar Total Stk Mkt Idx Invest3.29M3.17%14.84K
Vanguard Morn Total Stk Mkt Idx Investor3.28M3.16%18.29K
Vanguard Total Stock Mkt Idx Inv3.28M3.16%18.29K
Vanguard US Total Market Shares ETF2.13M2.79%196.50K
iShares Russell 2000 ETF2.45M2.36%-43.58K
State Street® SPDR® S&P® Biotech ETF2.42M2.33%5.56K
Fidelity Select Health Care1.69M2.21%90.00K
Xtrackers MSCI World Swap ETF 1C2.14M2.08%-13.47K
Pictet-Biotech P USD1.79M1.73%38.88K
American Funds SMALLCAP World A1.74M1.68%846.01K

Recent Insider Transactions


DateNameRoleActivityValue
Sep 02, 2026Ring Christine Chief Legal OfficerSell$138.42K
Sep 02, 2026Ring Christine Chief Legal OfficerSell$10.65K
Sep 01, 2026Hansen Gwenn Chief Scientific OfficerSell$36.98K
Aug 05, 2026Hansen Gwenn Chief Scientific OfficerSell$108.90K
Aug 04, 2026Hansen Gwenn Chief Scientific OfficerSell$64.34K

Insider Transactions Trends


DateBuySell
2026 Q3-13
2026 Q2-11
2026 Q1-9
2025 Q4-7
2025 Q3-4

NRIX Ownership FAQ


Who Owns Nurix Therapeutics?

Nurix Therapeutics shareholders are primarily institutional investors at 107.22%, followed by 1.08% insiders and -8.30% retail investors. The average institutional ownership in Nurix Therapeutics's industry, Biotech Stocks , is 379.61%, which Nurix Therapeutics falls below.

Who owns the most shares of Nurix Therapeutics?

Nurix Therapeutics’s largest shareholders are Blackrock (6.82M shares, 12.42%), Blackrock funding, inc. /de (8.77M shares, 7.97%), and Vestal point capital, lp (8.05M shares, 7.31%). Together, they hold 27.70% of Nurix Therapeutics’s total shares outstanding.

Does Blackrock own Nurix Therapeutics?

Yes, BlackRock owns 12.42% of Nurix Therapeutics, totaling 6.82M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 142.33M$. In the last quarter, BlackRock increased its holdings by 2.24M shares, a 48.90% change.

Who is Nurix Therapeutics’s biggest shareholder by percentage of total assets invested?

Redmile group is Nurix Therapeutics’s biggest shareholder by percentage of total assets invested, with 6.64% of its assets in 4.07M Nurix Therapeutics shares, valued at 98.83M$.

Who is the top mutual fund holder of Nurix Therapeutics shares?

Vanguard MStar Total Stk Mkt Idx Invest is the top mutual fund holder of Nurix Therapeutics shares, with 3.17% of its total shares outstanding invested in 3.29M Nurix Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools